Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: The ETHOS Study

Addiction

Volumn 111, Issue 2, 2016, Pages 311-319

  Grebely, Jason ^a   Alavi, Maryam ^a   Micallef, Michelle ^a   Dunlop, Adrian J ^b,c   Balcomb, Anne C ^d   Phung, Nghi ^e   Weltman, Martin D ^f,g   Day, Carolyn A ^g,h   Treloar, Carla ⁱ   Bath, Nicky ^j   Haber, Paul S ^g   Dore, Gregory J ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c Drug Alcohol Clinical Services   (Australia)

^d Kite St Community Health Centre   (Australia)

^e WESTERN SYDNEY LOCAL HEALTH DISTRICT   (Australia)

^f NEPEAN HOSPITAL   (Australia)

^g UNIVERSITY OF SYDNEY   (Australia)

^h ROYAL PRINCE ALFRED HOSPITAL   (Australia)

ⁱ UNIVERSITY OF NEW SOUTH WALES   (Australia)

^j New South Wales Government   (Australia)

more..

Author keywords

Antiviral therapy; Hepatitis C virus; Injecting drug use; Methadone; Opioid substitution treatment; People who inject drugs

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN; RIBAVIRIN;

ADULT; AGED; AMBULATORY CARE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG DEPENDENCE TREATMENT; FEMALE; HEALTH CARE DELIVERY; HEALTH CENTER; HEPATITIS C, CHRONIC; HUMAN; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; MULTICENTER STUDY; NEW SOUTH WALES; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PROCEDURES; SUBSTANCE ABUSE; TREATMENT OUTCOME;

ADULT; AGED; AMBULATORY CARE; ANTIVIRAL AGENTS; COMMUNITY HEALTH CENTERS; DELIVERY OF HEALTH CARE; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NEW SOUTH WALES; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT OUTCOME;

EID: 84954378990     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.13197     Document Type: Article

References (54)

1. Hajarizadeh B., Grebely J., Dore G. J. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013; 10: 553-62.
2. Grebely J., Dore G. J. What is killing people with hepatitis C virus infection? Semin Liver Dis 2011; 31: 331-9.
3. Grebely J., Tyndall M. W. Management of HCV and HIV infections among people who inject drugs. Curr Opin HIV AIDS 2011; 6: 501-7.
4. Grebely J., Raffa J. D., Lai C., Krajden M., Kerr T., Fischer B. et al. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepatitis 2009; 16: 352-8.
5. Mehta S. H., Genberg B. L., Astemborski J., Kavasery R., Kirk G. D., Vlahov D. et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health 2008; 33: 126-33.
6. Alavi M., Raffa J. D., Deans G. D., Lai C., Krajden M., Dore G. J. et al. Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents. Liver Int 2014; 34: 1198-206. doi: 10.1111/liv.12370 Epub 2013 Nov 20.
7. Iversen J., Grebely J., Topp L., Wand H., Dore G. J., Maher L. Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011. J Viral Hepat 2014; 21: 198-207. doi: 10.1111/jvh.12129.
8. Aspinall E., Corson S., Doyle J., Grebely J., Hutchinson S. J., Dore G. J. et al. Peginterferon and ribavirin treatment for chronic hepatitis C virus in people who inject drugs: a systematic review and meta-analysis. Clin Infect Dis 2013; 57: Suppl 2:S80-9. doi: 10.1093/cid/cit306.
9. Dimova R. B., Zeremski M., Jacobson I. M., Hagan H., Des Jarlais D. C., Talal A. H. Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clin Infect Dis 2013; 56: 806-16.
10. Robaeys G., Grebely J., Mauss S., Bruggmann P., Moussalli J., De Gottardi A. et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Clin Infect Dis 2013; 57(Suppl. 2): S129-37.
11. AASLD/IDSA. Recommendations for testing, managing, and treating hepatitis C; 2015. http://www.hcvguidelines.org/ (accessed 11 November 2015).
12. World Health Organization (WHO) Guidelines for the Screening, Care and Treatment of Persons With Hepatitis C Infection. Geneva, Switzerland: WHO; 2014.
13. European Association for Study of L EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014; 60: 392-420.
14. Grebely J., Robaeys G., Bruggmann P., Aghemo A., Backmund M., Bruneau J. et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Int J Drug Policy 2015; 26: 1028-38. doi: 10.1016/j.drugpo.2015.07.005.
15. Bruggmann P., Litwin A. H. Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all. Clin Infect Dis 2013; 57Suppl. 2: S56-61.
16. Litwin A. H., Harris K. A. Jr., Nahvi S., Zamor P. J., Soloway I. J., Tenore P. L. et al. Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. J Subst Abuse Treat 2009; 37: 32-40.
17. Hallinan R., Byrne A., Agho K., Dore G. J. Referral for chronic hepatitis C treatment from a drug dependency treatment setting. Drug Alcohol Depend 2007; 88: 49-53.
18. Grebely J., Knight E., Genoway K. A., Viljoen M., Khara M., Elliott D. et al. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. Eur J Gastroenterol Hepatol 2010; 22: 270-7.
19. Lindenburg C. E., Lambers F. A., Urbanus A. T., Schinkel J., Jansen P. L., Krol A. et al. Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project. Eur J Gastroenterol Hepatol 2011; 23: 23-31.
20. Harris K. A. Jr., Arnsten J. H., Litwin A. H. Successful integration of hepatitis C evaluation and treatment services with methadone maintenance. J Addict Med 2010; 4: 20-6.
21. Treloar C., Rance J., Grebely J., Dore G. J. Client and staff experiences of a co-located service for hepatitis C care in opioid substitution treatment settings in New South Wales, Australia. Drug Alcohol Depend 2013; 133: 529-34.
22. Alavi M., Grebely J., Micallef M., Dunlop A. J., Balcomb A. C., Day C. A. et al. Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study. Clin Infect Dis 2013; 57Suppl. 2: S62-9.
23. Darke S., Ward J., Hall W., Heather N., Wodak A. The Opiate Treatment Index (OTI) Researcher's Manual Technical Report Number 11. National Drug and Alcohol Research Centre: Sydney; 1991.
24. Lawrinson P., Copeland J., Indig D. The Brief Treatment Outcome Measure: Opioid Maintenance Pharmacotherapy (BTOM) Manual NDARC Technical Report no 156. Sydney: University of New South Wales; 2003.
25. Lawrinson P., Copeland J., Indig D. Development and validation of a brief instrument for routine outcome monitoring in opioid maintenance pharmacotherapy services: the brief treatment outcome measure (BTOM). Drug Alcohol Depend 2005; 80: 125-33.
26. Bush K., Kivlahan D. R., McDonell M. B., Fihn S. D., Bradley K. A. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Arch Intern Med 1998; 158: 1789.
27. Wai C. T., Greenson J. K., Fontana R. J., Kalbfleisch J. D., Marrero J. A., Conjeevaram H. S. et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
28. Shaheen A. A. M., Myers R. P. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology 2007; 46: 912-21.
29. Chou R., Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. A systematic review. Ann Intern Med 2013; 158: 807-20.
30. Sterling R. K., Lissen E., Clumeck N., Sola R., Correa M. C., Montaner J. et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-25.
31. Adler M., Gulbis B., Moreno C., Evrard S., Verset G., Golstein P. et al. The predictive value of FIB-4 versus FibroTest, APRI, FibroIndex and Forns index to noninvasively estimate fibrosis in hepatitis C and nonhepatitis C liver diseases. Hepatology 2008; 47: 762-3.
32. Kim B. K., Kim D. Y., Park J. Y., Ahn S. H., Chon C. Y., Kim J. K. et al. Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients. Liver Int 2010; 30: 546-53.
33. Alavi M., Micallef M., Fortier E., Dunlop A. J., Balcomb A. C., Day C. A. et al. Effect of treatment willingness on specialist assessment and treatment uptake for hepatitis C virus infection among people who use drugs: the ETHOS study. J Viral Hepat. 2015; 22: 914-25. doi: 10.1111/jvh.12415.
34. Martin N. K., Foster G. R., Vilar J., Ryder S., Cramp M. E., Gordon F. et al. HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact. J Viral Hepat 2015; 22: 399-408. doi: 10.1111/jvh.12338.
35. Grebely J., Genoway K., Khara M., Duncan F., Viljoen M., Elliott D. et al. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. Int J Drug Policy 2007; 18: 437-43.
36. Grebely J., Raffa J. D., Meagher C., Duncan F., Genoway K. A., Khara M. et al. Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users. J Gastroenterol Hepatol 2007; 22: 1519-25.
37. Sasadeusz J. J., Dore G., Kronborg I., Barton D., Yoshihara M., Weltman M. Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy. Addiction 2011; 106: 977-84.
38. Charlebois A., Lee L., Cooper E., Mason K., Powis J. Factors associated with HCV antiviral treatment uptake among participants of a community-based HCV programme for marginalized patients. J Viral Hepatitis 2012; 19: 836-42.
39. Witteck A., Schmid P., Hensel-Koch K., Thurnheer M. C., Bruggmann P., Vernazza P.\ et al. Management of hepatitis C virus (HCV) infection in drug substitution programs. Swiss Med Wkly 2011; 141: w13193.
40. Brunner N., Senn O., Rosemann T., Falcato L., Bruggmann P. Hepatitis C treatment for multimorbid patients with substance use disorder in a primary care-based integrated treatment centre: a retrospective analysis. Eur J Gastroenterol Hepatol 2013; 25: 1300-7.
41. Seidenberg A., Rosemann T., Senn O. Patients receiving opioid maintenance treatment in primary care: successful chronic hepatitis C care in a real world setting. BMC Infect Dis 2013; 13: 9.
42. Fried M. W., Shiffman M. L., Reddy K. R., Smith C., Marinos G., Goncales F. L. Jr. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
43. Manns M. P., McHutchison J. G., Gordon S. C., Rustgi V. K., Shiffman M., Reindollar R. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
44. McHutchison J. G., Manns M., Patel K., Poynard T., Lindsay K. L., Trepo C. et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-9.
45. Sylvestre D. L., Clements B. J. Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. Eur J Gastroenterol Hepatol 2007; 19: 741-7.
46. Grebely J., Matthews G. V., Hellard M., Shaw D., van Beek I., Petoumenos K. et al. Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users. J Hepatol 2011; 55: 76-85.
47. Marcellin P., Chousterman M., Fontanges T., Ouzan D., Rotily M., Varastet M. et al. Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study. Liver Int 2011; 31: 516-24.
48. Sasadeusz J. J., Dore G., Kronborg I., Barton D., Yoshihara M., Weltman M. Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy. Addiction 2011; 106: 977-84. doi: 10.1111/j.1360-0443.2010.03347.x.
49. Manolakopoulos S., Deutsch M. J., Anagnostou O., Karatapanis S., Tiniakou E., Papatheodoridis G. V. et al. Substitution treatment or active intravenous drug use should not be contraindications for antiviral treatment in drug users with chronic hepatitis C. Liver Int 2010; 30: 1454-60.
50. Dore G. J., Hellard M., Matthews G. V., Grebely J., Haber P. S., Petoumenos K. et al. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology 2010; 138: 123-35, e121-122.
51. Sylvestre D. L., Litwin A. H., Clements B. J., Gourevitch M. N. The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. J Subst Abuse Treat 2005; 29: 159-65.
52. Bruggmann P., Falcato L., Dober S., Helbling B., Keiser O., Negro F. et al. Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients. J Viral Hepatitis 2008; 15: 747-52.
53. Alavi M., Spelman T., Matthews G. V., Haber P. S., Day C., van Beek I. et al. Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C. Int J Drug Policy 2015.
54. Cunningham E. B., Applegate T. L., Lloyd A. R., Dore G. J., Grebely J. Mixed HCV infection and reinfection in people who inject drugs-impact on therapy. Nat Rev Gastroenterol Hepatol 2015; 12: 218-30. doi: 10.1038/nrgastro.2015.36.